Drug development for Alzheimer's disease
K Lao, N Ji, X Zhang, W Qiao, Z Tang… - Journal of drug …, 2019 - Taylor & Francis
Alzheimer's disease (AD) is a chronic neurodegenerative disease, which is considered as
one of the most intractable medical problems with heavy social and economic costs. The …
one of the most intractable medical problems with heavy social and economic costs. The …
[HTML][HTML] Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease
T Athar, K Al Balushi, SA Khan - Molecular biology reports, 2021 - Springer
Alzheimer's disease (AD) is a neurodegenerative old age disease that is complex,
multifactorial, unalterable, and progressive in nature. The currently approved therapy …
multifactorial, unalterable, and progressive in nature. The currently approved therapy …
Novel pharmaceutical approaches in dementia
Dementia is major neurocognitive disorder in which 95% of patients is diagnosed with
Alzheimer's disease, stroke-induced neurodegeneration, or dementia with Lewy Bodies …
Alzheimer's disease, stroke-induced neurodegeneration, or dementia with Lewy Bodies …
[HTML][HTML] Alzheimer's disease drug-development pipeline: few candidates, frequent failures
JL Cummings, T Morstorf, K Zhong - Alzheimer's research & therapy, 2014 - Springer
Introduction Alzheimer's disease (AD) is increasing in frequency as the global population
ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors …
ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors …
[HTML][HTML] Drug candidates in clinical trials for Alzheimer's disease
SY Hung, WM Fu - Journal of biomedical science, 2017 - Springer
Alzheimer's disease (AD) is a major form of senile dementia, characterized by progressive
memory and neuronal loss combined with cognitive impairment. AD is the most common …
memory and neuronal loss combined with cognitive impairment. AD is the most common …
[HTML][HTML] Treatment of Alzheimer's disease: beyond symptomatic therapies
FR Buccellato, M D'Anca, GM Tartaglia… - International Journal of …, 2023 - mdpi.com
In an ever-increasing aged world, Alzheimer's disease (AD) represents the first cause of
dementia and one of the first chronic diseases in elderly people. With 55 million people …
dementia and one of the first chronic diseases in elderly people. With 55 million people …
[HTML][HTML] Clinical trials of new drugs for Alzheimer disease
LK Huang, SP Chao, CJ Hu - Journal of biomedical science, 2020 - Springer
Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of
the disease and continual increase in patient numbers, developing effective therapies to …
the disease and continual increase in patient numbers, developing effective therapies to …
[HTML][HTML] Current and future therapeutic strategies for Alzheimer's disease: An overview of drug development bottlenecks
Y Peng, H Jin, Y Xue, Q Chen, S Yao, M Du… - Frontiers in aging …, 2023 - frontiersin.org
Alzheimer's disease (AD) is the most common chronic neurodegenerative disease
worldwide. It causes cognitive dysfunction, such as aphasia and agnosia, and mental …
worldwide. It causes cognitive dysfunction, such as aphasia and agnosia, and mental …
Therapeutics of Alzheimer's disease: Past, present and future
Alzheimer's disease (AD) is the most common cause of dementia worldwide. The etiology is
multifactorial, and pathophysiology of the disease is complex. Data indicate an exponential …
multifactorial, and pathophysiology of the disease is complex. Data indicate an exponential …
Elucidating treatment of Alzheimer's disease via different receptors
M Shahnawaz Khan, M Amjad Kamal… - Current topics in …, 2017 - ingentaconnect.com
Alzheimer's disease (AD) is an irreversible multifaceted neurodegenerative disorder that
gradually degrades neuronal cells. Presently, it is the most common reason for the memory …
gradually degrades neuronal cells. Presently, it is the most common reason for the memory …